Like ePharmaSolutions, Inc.

closed 9/24/2014 via PR Newswire

The WIRB-Copernicus Group, acquired ePharmaSolutions, Inc.

synopsis: WIRB-Copernicus Group (WCG), the world's largest provider of regulatory and ethical review services for clinical research, announced that ePharmaSolutions (ePS) has joined its group of companies. ePharmaSolutions is a leading provider of eClinical solutions and technology-enabled services that improve the conduct of clinical trials.
buyer parent: Arsenal Capital Partners
buyer: The WIRB-Copernicus Group
WIRB-Copernicus Group (WCG) is the world's largest provider of regulatory and ethical solutions for clinical research, including Institutional Review Board (IRB) and Institutional Biosafety Committee (IBC) review. "
target: ePharmaSolutions, Inc.
ePharmaSolutions is a leading provider of eClinical solutions and specialty clinical services that help improve the way trial sites are selected, trained, activated and managed to exceed enrollment goals.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 5/30/2021 via BNC Analysis

CSAM Health AS, acquired MedSciNet

synopsis: CSAM Health Group AS, the leading provider of niche eHealth solutions in the Nordics, announced that they have acquired MedSciNet AB, a provider of benchmark eHealth solutions within clinical research.
buyer: CSAM Health AS (OB:CSAM:$30.36)
CSAM is a leading Norwegian company in the specialized eHealth market with a unique blend of best in class innovative technology, and outstanding human skills. Their diverse portfolio of software solutions enables healthcare providers to access relevant clinical information at the point of care. "
target: MedSciNet
MedSciNet is a Stockholm based company specialising in design and development of web applications and on-line database systems for clinical trials and studies, quality registries, medical bio-banks, and other solutions within the medical field.
price ($mm)
$2.88
rev ($mm)
$2
EBITDA ($mm)
EV / rev
1.7x
EV / EBITDA
announced 5/27/2021 via PR Newswire

Thoma Bravo, LLC, will acquire Greenphire, Inc

synopsis: Thoma Bravo, a leading private equity investment firm focused on the software and technology-enabled services sector, has reached an agreement to acquire Greenphire, the global leader in financial lifecycle management software for clinical trials, from The Riverside Company.
buyer: Thoma Bravo, LLC
Thoma Bravo is a leading private equity firm focused on the software and technology-enabled services sectors. Thoma Bravo partners with a company’s management team to implement operating best practices, invest in growth initiatives and make acquisitions intended to accelerate revenue and earnings. "
target parent: The Riverside Company
target: Greenphire, Inc
Greenphire is the leader in global clinical trial financial process automation. Greenphire's best-in-class solutions optimize clinical trial performance by streamlining payment and logistical workflows from sponsors and CROs to sites and patients.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/19/2021 via GlobeNewswire

Scarritt Group Inc., acquired TrialTech Medical Inc.

synopsis: Scarritt Group Inc., a technology-enabled leader in the planning and execution of meetings for Investigators and Coordinators of clinical trials, has acquired TrialTech Medical Inc, a leader in the application of cloud- based software and artificial intelligence enabled digital marketing for the recruitment of eligible subjects for clinical trials.
buyer: Scarritt Group Inc.
Scarritt Group is a technology-enabled, full service meeting planning and logistics company specializing in delivering clinical trial meetings worldwide. "
target: TrialTech Medical Inc.
TrialTech Medical is a software and services company supporting the pharmaceutical, biotechnology and medical device industries. They work in coordination with their clients' medical and clinical operations teams to optimize the process of clinical trial planning, recruitment and enrollment.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/20/2019 via BNC Analysis

Monterro, acquired Viedoc

synopsis: Monterro, the leading B2B software investor in the Nordics, has acquired a majority stake in Viedoc, a modern and sophisticated electronic data capture (EDC) system. Viedoc enables researchers to gather and evaluate clinical trial data more efficiently.
buyer: Monterro
Sweden-based Monterro is the leading B2B software investor in the Nordics, with a mission to turn software companies into market leaders. With operational experience from successfully developing and running companies, Monterro actively supports its portfolio companies in all aspects of growth. "
target: Viedoc
Viedoc is a modern and sophisticated electronic data capture (EDC) system. Viedoc enables researchers to gather and evaluate clinical trial data more efficiently. Their powerful EDC system has been used in over 2000 trials in more than 75 countries in all therapeutic areas and clinical phases.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 10/24/2019 via BNC Analysis

TrialScope, acquired Clinical Trial Connect, LLC

synopsis: TrialScope has acquired Clinical Trial Connect, a platform used by disease foundations and advocacy groups that connects their community members to relevant clinical trials. As part of the acquisition, founder Mike Wenger will share his technological expertise as part of the TrialScope team.
buyer: TrialScope
TrialScope is the global leader in clinical trial transparency and compliance. TrialScope's tools and systems enable their customers to improve their clinical trial process, mitigate registry and lifecycle risk, and ultimately achieve greater business success. "
target: Clinical Trial Connect, LLC
Clinical Trial Connect is a platform used by disease foundations and advocacy groups that connects their community members to relevant clinical trials. Clinical Trial Connect was founded by Mike Wenger, who developed his own algorithm for matching patients to clinical trials.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 8/28/2019 via BNC Analysis

JLL Partners, Water Street Healthcare Partners, acquired THREAD Research

synopsis: Water Street Healthcare Partners and JLL Partners have acquired Orange County, California-based THREAD, a provider of technology that enables virtual research approaches to modernize clinical studies and registries.
buyer: JLL Partners
buyer: Water Street Healthcare Partners
JLL Partners is a middle-market private equity firm with a 30-year track record of building and transforming businesses. Water Street is a strategic investor focused exclusively on healthcare. The firm has a strong record of building market-leading companies across key growth sectors in healthcare. "
target: THREAD Research
THREAD is a virtual research platform used by biopharma, CROs, non-profit researchers, and life science organizations to capture global clinical study data in between, as well as during and instead of clinic visits.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 7/17/2019 via GlobeNewswire

Anju Software, will acquire OmniComm Systems, Inc.

synopsis: Anju Software, a leading provider of comprehensive software solutions to the life sciences industry, will be acquiring OmniComm, a healthcare technology company that provides web-based electronic data capture and eClinical solutions and related value-added services.
buyer parent: ABRY Partners, LLC
buyer: Anju Software
Anju Software, Inc. is a leading provider of comprehensive software solutions to the life sciences industry that provides an integrated platform spanning clinical operations, medical affairs, and commercial divisions, including integrated data intelligence. "
target: OmniComm Systems, Inc. (OTCPK:OMCM:$14,891.70)
OmniComm is a healthcare technology company that provides web-based electronic data capture and eClinical solutions and related value-added services to pharmaceutical and biotech companies, contract research organizations, and other clinical trial sponsors.
price ($mm)[EV]
$72 [$81]
rev ($mm)
$25
EBITDA ($mm)
$2
EV / rev
3.4x
EV / EBITDA
46.2x
announced 6/12/2019 via BusinessWire

Dassault Systemes, will acquire Medidata

synopsis: Dassault Systèmes, a provider of solutions that transform the way products are designed, provided and supported, will be acquiring Medidata, a provider of a platform for clinical development, commercial, and real-world data.
buyer: Dassault Systemes (ENXTPA:DSY:$5,323.17)
Based in France, Dassault Systèmes provides clients with virtual universes to imagine sustainable innovations. Its solutions transform the way products are designed, produced, and supported. They foster social innovation, expanding possibilities for the virtual world to improve the real world. "
target: Medidata (MDSO:$660.00)
Medidata is leading the digital transformation of life science, with a platform for clinical development, commercial, and real-world data. Powered by artificial intelligence, Medidata helps accelerate value, minimize risk and optimize outcomes.
price ($mm)[EV]
$5,825 [$5,822]
rev ($mm)
$660
EBITDA ($mm)
$81
EV / rev
8.8x
EV / EBITDA
72.2x
closed 4/10/2019 via BNC Analysis

TriNetX, acquired Custodix N.V.

synopsis: TriNetX has acquired Custodix, a Belgian-based provider of clinical trial patient recruitment solutions. TriNetX is a global health research network that has revolutionised clinical research. Custodix is a provider of clinical trial patient recruitment solutions offering a range of solutions for ensuring compliance.
buyer: TriNetX
TriNetX is the global health research network enabling healthcare organizations, biopharma and CROs to collaborate, enhance trial design, accelerate recruitment and bring new therapies to market faster. "
target: Custodix N.V.
Custodix is a Belgian provider of clinical trial patient recruitment solutions offering a range of solutions for ensuring compliance with European and US data protection legislation and security best practices.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 10/17/2018 via Company Press Release

Oracle Corporation, will acquire GoBalto

synopsis: Oracle announced that it has entered into an agreement to acquire goBalto, which delivers leading cloud solutions to accelerate clinical trials by streamlining and automating the selection and set up of the best performing clinical research sites to conduct trials.
buyer: Oracle Corporation (ORCL:$39,766.00)
Oracle is a computer technology corporation developing and marketing computer hardware systems and enterprise software products. By eliminating complexity and simplifying IT, Oracle enables its customers to accelerate innovation and create added value for their customers. "
target: GoBalto
goBalto, Inc. is an award winning, venture backed group of industry veterans that creates simple, focused software for the global drug trial industry. Its products offer drug trial sponsors and clinical research organizations the fastest, easiest possible way to start clinical studies on the web.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/21/2018 via BusinessWire

Anju Software, acquired Sylogent

synopsis: Anju Software Inc., a life sciences software platform backed by Providence Equity Partners, has acquired Sylogent. Sylogent delivers cloud based state of the art software solutions and business services to the pharmaceutical industry focused specifically on the information required to bring a product to market.
buyer parent: Providence Equity Partners Inc.
buyer: Anju Software
Anju Software is a life sciences enterprise software platform focused on delivering exceptional business application solutions. Anju was founded by professionals with deep software domain expertise and a track record of building software platforms through strategic acquisitions and organic growth. "
target: Sylogent
Sylogent delivers software and business services to the pharmaceutical industry focused specifically on the information required to bring a product to market. They ensure the timely completion of critical information, maximize compliance goals and reduce risk management liability.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 8/9/2017 via Company Press Release

PRA Health Sciences, acquired Parallel 6

synopsis: HCAP Partners, a California-based mezzanine debt and private equity firm, announced that it has exited its investment in Parallel 6, Inc. (“P6”), a mobile clinical (“mClinical”) SaaS platform designed to recruit, enroll, engage and manage patients in clinical trials. P6 was sold to PRA Health Sciences, Inc.
buyer parent: Kohlberg Kravis Roberts & Co.
buyer: PRA Health Sciences (PRAH:$1,698.48)
PRA Health Sciences, Inc. is one of the world’s leading global CROs by revenue, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. Since 2000, PRA has participated in approximately 3,500 clinical trials worldwide. "
target parent: HCAP Partners
target: Parallel 6
Parallel 6’s technology digitally enrolls, engages and manages patients using mobile endpoints. Sponsors and clinical research organizations can connect directly with and manage patients anywhere in the world, seamlessly integrating into their daily lives.
price ($mm)
$40
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/16/2016 via BNC Analysis

DrugDev, acquired SecureConsent

synopsis: DrugDev has acquired SecureConsent, a developer of mobile e-consent software. SecureConsent replaces the paper methods that have historically been used to secure informed consent from patients participating in drug studies with an e-consent method that uses tablets and other mobile devices.
buyer: DrugDev
DrugDev streamlines engagement among sponsors, CROs and doctors to advance the common goal of doing more trials. Through the creation of global, standardized processes DrugDev is consistently and efficiently transforming the way drug developers identify, engage and pay investigators. "
target: SecureConsent
The software products developed by Secure Consent replace the paper methods that have historically been used to secure informed consent from patients participating in drug studies with an e-consent method that uses tablets and other mobile devices.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/19/2016 via PR Newswire

BioClinica, Inc., acquired Clinverse, Inc.

synopsis: Bioclinica, Inc., a specialty trials services and technology provider, announced it has acquired Clinverse, Inc. Clinverse automates and manages the entire financial lifecycle of global clinical trials for contract research organizations and pharmaceutical companies. Its suite of products pays clinical trial sites, vendors and their subjects.
buyer: BioClinica, Inc.
Bioclinica is a specialty services provider that utilizes expertise and technology to create clarity in the clinical trial process. Bioclinica is organized into three business segments to deliver focused service and multifaceted technologies. "
target: Clinverse, Inc.
Clinverse, Inc. architected the industry's first automated financial management technology solution for clinical trials. Their solution standardizes clinical trial financial management for millions of financial transactions across the globe, including clinical site payments.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/17/2015 via PR Web

Aris Global LLC, acquired Medsight Solutions Inc.

synopsis: ArisGlobal®, a leading provider of Cloud solutions to life sciences companies, is pleased to announce that it has acquired Medsight Solutions, including the revolutionary integrated risk management solution, Medsight Sapphire (now known as ArisGlobal agBalance™).
buyer: Aris Global LLC
For more than 20 years, ArisGlobal has led in the development of innovative software solutions for pharmacovigilance & safety, regulatory affairs, clinical research and medical information. "
target: Medsight Solutions Inc.
Medsight Solutions Inc. is a life sciences solutions and professional services company with specialties in Clinical trial optimization, Benefit-risk assessment and Compliance monitoring.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 10/3/2014 via PR Newswire

PAREXEL International Corporation, acquired ClinIntel Ltd.

synopsis: PAREXEL International Corporation, a global clinical research organization, announced that the Company has acquired all of the outstanding equity securities of privately-owned ClinIntel, a provider of clinical Randomization and Trial Supply Management (RTSM) services, based in the United Kingdom.
buyer: PAREXEL International Corporation (PRXL:$1,939.36)
PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. "
target: ClinIntel Ltd.
Headquartered in the United Kingdom, ClinIntel is a provider of clinical Randomization and Trial Supply Management (RTSM) services. The company was founded in 2009, and works with biopharmaceutical companies and contract research organizations.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/16/2014 via PR Newswire

BioClinica, Inc., acquired Blueprint Clinical

synopsis: BioClinica®, Inc., a leading provider of eClinical Solutions for the Pharmaceutical Industry, has announced the acquisition of Blueprint Clinical, a fast-growing company offering ground-breaking technology and extensive expertise to drive successful Risk-Based Monitoring (RBM) strategies for clinical trials.
buyer parent: JLL Partners
buyer: BioClinica, Inc.
BioClinica, Inc. is a leading global provider of integrated clinical trial management technologies including eClinical solutions for clinical trial supply management, forecasting and optimization, electronic data capture, randomization, and clinical trial management. "
target: Blueprint Clinical
Blueprint Clinical, Inc. creates Software-as-a-Service tools that help improve monitoring of clinical trials. Their first product, Blueprint Clinical Compass™, ultimately allows risk based monitoring implementation thereby improving quality and efficiency of clinical trials.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/24/2012 via BusinessWire

IMS Health Incorporated, acquired DecisionView, Inc.

synopsis: IMS Health has acquired DecisionView, a software solutions company that helps life sciences organizations plan and track patient enrollment for clinical trials around the world. DecisionView offers its clients an innovative suite of decision support tools to improve the speed, efficiency and performance of clinical trial planning and management.
buyer parent: TPG Capital
buyer: IMS Health Incorporated (NYSE:IQV:$10,412.00)
IMS Health is the leading provider of information services for the healthcare industry around the world. The company draws on its global technology infrastructure and unique combination of in-depth, analytics, and consulting platforms to help clients better understand the value of medicines. "
target parent: Granite Ventures, LLC
target: DecisionView, Inc.
DecisionView develops web-based software solutions that enable life sciences organizations around the world to improve clinical trial performance. Its flagship solution, StudyOptimizer®, is a web-based solution that helps clinical trial organizations plan, forecast and track patient enrollment.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 3/29/2012 via Market Wire

Oracle Corporation, will acquire ClearTrial, LLC.

synopsis: Oracle announced that it has entered into an agreement to acquire ClearTrial, a leading provider of cloud-based Clinical Trial Operations (CTO) applications that make the planning, sourcing, and tracking of clinical projects and financial performance faster and more accurate.
buyer: Oracle Corporation (ORCL:$39,766.00)
Oracle Corporation is the world's largest enterprise software company. The company is a leading provider of systems software, including database management, application development, and application server software. "
target: ClearTrial, LLC.
ClearTrial, LLC provides software-as-a-service based Clinical Trial Operations software for planning, forecasting, and tracking clinical project and financial performance. The company serves biopharmaceutical companies, CROs, medical device companies, and small biotechs worldwide.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 9/24/2014 via PR Newswire

The WIRB-Copernicus Group, acquired ePharmaSolutions, Inc.

synopsis: WIRB-Copernicus Group (WCG), the world's largest provider of regulatory and ethical review services for clinical research, announced that ePharmaSolutions (ePS) has joined its group of companies. ePharmaSolutions is a leading provider of eClinical solutions and technology-enabled services that improve the conduct of clinical trials.
buyer parent: Arsenal Capital Partners
buyer: The WIRB-Copernicus Group
WIRB-Copernicus Group (WCG) is the world's largest provider of regulatory and ethical solutions for clinical research, including Institutional Review Board (IRB) and Institutional Biosafety Committee (IBC) review. "
target: ePharmaSolutions, Inc.
ePharmaSolutions is a leading provider of eClinical solutions and specialty clinical services that help improve the way trial sites are selected, trained, activated and managed to exceed enrollment goals.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/20/2012 via PR Newswire

ePharmaSolutions, Inc., acquired Polaris Biopharma Consulting

synopsis: ePharmaSolutions announced the acquisition of Polaris BioPharma Consulting, a leading global patient recruitment and retention firm headquartered in Slough, UK. Polaris Biopharma was founded in 1999 as a boutique patient recruitment and retention firm supporting global pharmaceutical companies.
buyer: ePharmaSolutions, Inc.
ePharmaSolutions is a leading provider of technology-based clinical services that helps improve the way sites are selected, trained, activated and managed to exceed enrollment goals. ePharmaSolutions won the 2009 Bio-IT World Award for best clinical trial technology. "
target: Polaris Biopharma Consulting
Polaris Biopharma Consulting is a boutique patient recruitment and retention firm. Polaris has helped large and mid-sized pharmaceutical companies and CROs develop and deploy hundreds of global feasibility, trial optimisation and patient recruitment programs in every major therapeutic area.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 12/3/2020 via PR Newswire

The WIRB-Copernicus Group, acquired Trifecta

synopsis: WCG has acquired Trifecta Clinical, a proven leader in technology-enabled clinical trial solutions, including its comprehensive site communication platform InvestigatorSpace, virtual training programs, and safety documentation services. The acquisition of Trifecta expands the range of specialized services and solutions WCG can offer to companies.
buyer parent: Leonard Green & Partners, L.P.
buyer: The WIRB-Copernicus Group
WCG is the world's leading provider of solutions that measurably improve the quality and efficiency of clinical research. Comprised of two divisions, WCG enables biopharmaceutical companies, CROs, and institutions to advance the delivery of new treatments and therapies to patients. "
target: Trifecta
Trifecta is a global leader and a trusted partner with decades of experience in clinical trial technology solutions for leading pharmaceutical, biotech and clinical research organizations. Trifecta offers a fully integrated training, safety, and communication platform built from the ground up.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/27/2019 via PR Newswire

The WIRB-Copernicus Group, acquired Waife & Associates, Inc.

synopsis: WIRB-Copernicus Group (WCG) has acquired Waife & Associates, Inc. (W&A), a provider of management consulting services for biopharmaceutical clinical research clients. W&A focuses on making clinical development more efficient and productive through improvements in organization, process, and technology.
buyer parent: Arsenal Capital Partners
buyer: The WIRB-Copernicus Group
WCG (WIRB-Copernicus Group) is the world's leading provider of solutions that improve the quality and efficiency of clinical research. WCG enables biopharmaceutical companies, clinical research organizations, and institutions to accelerate the delivery of new treatments and therapies to patients. "
target: Waife & Associates, Inc.
Waife & Associates (W&A) provides the clinical research industry with management and operational consulting delivered with senior domain expertise. W&A designs cost-effective solutions for clinical operations and data management, and all related functions and software technologies involved.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/30/2019 via Company Press Release

The WIRB-Copernicus Group, acquired First Clinical Research LLC

synopsis: The WIRB-Copernicus Group®’s (WCG™) Market Intelligence & Insights Division has acquired First Clinical Research LLC, organizer of the MAGI (Model Agreements & Guidelines International) Clinical Research Conference. First Clinical also publishes the Journal of Clinical Research Best Practices.
buyer parent: Arsenal Capital Partners
buyer: The WIRB-Copernicus Group
WIRB-Copernicus Group (WCG) is the world’s leading provider of solutions that measurably improve the quality and efficiency of clinical research. WCG enables institutions to accelerate the delivery of new treatments and therapies to patients, while maintaining high safety standards. "
target: First Clinical Research LLC
First Clinical Research LLC is the organizer of the MAGI (Model Agreements & Guidelines International) Clinical Research Conference, which unifies the clinical research ecosystem by facilitating communication and the sharing of best practices among members.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/25/2018 via Company Press Release

The WIRB-Copernicus Group, acquired KMR Group

synopsis: WIRB-Copernicus Group (WCG), the leading provider of solutions to measurably improve the quality and efficiency of clinical research, has acquired KMR Group, a global leader in the provision and analysis of benchmarking and other data for the biopharmaceutical industry.
buyer parent: Arsenal Capital Partners
buyer: The WIRB-Copernicus Group
WIRB-Copernicus Group (WCG) is the world's leading provider of solutions to measurably improve the quality and efficiency of clinical research. WCG enables biopharmaceutical companies, CROs and institutions to accelerate the delivery of new treatments and therapies to patients. "
target: KMR Group
KMR Group is a global leader in the provision and analysis of benchmarking and other data for the biopharmaceutical industry. KMR offers leading-edge data, products, and services in the form of reports and on-line tools that inform client strategy and productivity as well as day-to-day operations.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/25/2018 via Company Press Release

The WIRB-Copernicus Group, acquired Metrics Champion Consortium

synopsis: WIRB-Copernicus Group (WCG), the leading provider of solutions to measurably improve the quality and efficiency of clinical research, has acquired Metrics Champion Consortium (MCC), an association dedicated to the development of standardized performance metrics to improve clinical trials.
buyer parent: Arsenal Capital Partners
buyer: The WIRB-Copernicus Group
WIRB-Copernicus Group (WCG) is the world's leading provider of solutions to measurably improve the quality and efficiency of clinical research. WCG enables biopharmaceutical companies, CROs and institutions to accelerate the delivery of new treatments and therapies to patients. "
target: Metrics Champion Consortium
Metrics Champion Consortium (MCC) is an association dedicated to the development of standardized performance metrics to improve clinical trials. MCC provides the collaborative environment for biopharmaceutical and device sponsors, service providers, and sites to improve clinical trial development.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/27/2018 via Company Press Release

The WIRB-Copernicus Group, acquired ACI Clinical

synopsis: WIRB-Copernicus Group, the world’s leading provider of solutions that measurably improve the quality and efficiency of clinical research, has acquired ACI Clinical, a specialty provider of clinical trial committees and clinical trial advisory services.
buyer parent: Arsenal Capital Partners
buyer: The WIRB-Copernicus Group
WIRB-Copernicus Group (WCG) is the world's leading provider of solutions to measurably improve the quality and efficiency of clinical research. WCG enables biopharmaceutical companies, CROs and institutions to accelerate the delivery of new treatments and therapies to patients. "
target: ACI Clinical
ACI Clinical is a specialty provider of clinical trial committees and clinical trial advisory services. ACI Clinical specializes in clinical and safety consulting, including full service Endpoint Adjudication Committees and Data Monitoring Committees.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 8/2/2017 via PR Newswire

The WIRB-Copernicus Group, purchased ConsentNow from Patient Genesis

synopsis: WIRB-Copernicus Group announced that it has acquired Patient Genesis' ConsentNow™ eConsent technology. ConsentNow is a web and mobile-based technology platform that allows pharmaceutical, healthcare, or medical device makers to disclose critical information in an easy-to-use, patient-friendly format.
buyer parent: Arsenal Capital Partners
buyer: The WIRB-Copernicus Group
WIRB-Copernicus Group (WCG) is the world's leading provider of solutions to measurably improve the quality and efficiency of clinical research. WCG enables biopharmaceutical companies, CROs and institutions to accelerate the delivery of new treatments and therapies to patients. "
seller: Patient Genesis
The acquisition includes the ConsentNow™ eConsent technology from Patient Genesis. ConsentNow is a web and mobile-based technology platform that allows pharmaceutical, healthcare, or medical device makers to disclose critical information in an easy-to-use, patient-friendly format.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 5/9/2017 via PR Newswire

The WIRB-Copernicus Group, acquired MedAvante, Inc.

synopsis: WIRB-Copernicus Group® (WCG™), the world's leading provider of solutions that measurably improve the quality and efficiency of clinical research, announced that it has acquired MedAvante. MedAvante is a clinical science-driven data services company dedicated to maximizing signal detection in global clinical trials.
buyer parent: Arsenal Capital Partners
buyer: The WIRB-Copernicus Group
WIRB-Copernicus Group (WCG) is the world's leading provider of solutions that measurably improve the quality and efficiency of clinical research. WCG enables biopharmaceutical companies, CROs, and institutions to accelerate the delivery of new treatments and therapies to patients. "
target: MedAvante, Inc.
MedAvante is a clinical science-driven data services company dedicated to maximizing signal detection in clinical trials. With Virgil™, its electronic clinical outcome assessment (eCOA) platform, clinical research sponsors are able to maximize outcome data quality & increase operational efficiency.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 5/9/2017 via PR Newswire

The WIRB-Copernicus Group, acquired ProPhase, LLC

synopsis: WIRB-Copernicus Group® (WCG™), the world's leading provider of solutions that measurably improve the quality and efficiency of clinical research, announced that it has acquired ProPhase. ProPhase is a global provider of measurement-related specialty solutions in clinical trials.
buyer parent: Arsenal Capital Partners
buyer: The WIRB-Copernicus Group
WIRB-Copernicus Group (WCG) is the world's leading provider of solutions that measurably improve the quality and efficiency of clinical research. WCG enables biopharmaceutical companies, CROs, and institutions to accelerate the delivery of new treatments and therapies to patients. "
target: ProPhase, LLC
ProPhase is a global provider of measurement-related specialty solutions in clinical trials. For over a decade, ProPhase has focused on applying innovation to optimize the selection, use, and analysis of behavioral endpoints to mitigate trial risk and maximize the likelihood of study success.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 5/2/2017 via PR Newswire

The WIRB-Copernicus Group, acquired ThreeWire, Inc.

synopsis: WIRB-Copernicus Group, the leading provider of solutions that improve the quality & efficiency of clinical research, has acquired ThreeWire, the patient recruitment, enrollment, & retention firm that uses a systematic approach to help biopharmaceutical, medical device companies & clinical research organizations achieve their clinical trial goals.
buyer parent: Arsenal Capital Partners
buyer: The WIRB-Copernicus Group
WIRB-Copernicus Group (WCG) is the world's leading provider of solutions that measurably improve the quality and efficiency of clinical research. WCG enables biopharmaceutical companies, CROs, and institutions to accelerate the delivery of new treatments and therapies to patients. "
target: ThreeWire, Inc.
ThreeWire is the global patient recruitment, enrollment, and retention firm that uses a systematic, patient-focused approach to help biopharmaceutical and medical device companies and clinical research organizations achieve their clinical trial enrollment and retention goals.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/22/2016 via PR Newswire

The WIRB-Copernicus Group, acquired CenterWatch, Inc.

synopsis: WIRB-Copernicus Group, one of the world's leading providers of solutions that measurably improve the quality and efficiency of clinical research, announced its acquisition of CenterWatch, the leading provider of clinical trial industry news and information. CenterWatch provides clinical trials information to clinical research professionals.
buyer parent: Arsenal Capital Partners
buyer: The WIRB-Copernicus Group
WIRB-Copernicus Group (WCG) is one of the world's leading providers of solutions that measurably improve the quality and efficience of clinical research. WCG enables biopharmaceutical companies, Clinical Services Organizations and institutions to accelerate the delivery of new treatments. "
target: CenterWatch, Inc.
CenterWatch is the recognized global leader in providing clinical trials information to a broad and influential spectrum of clinical research professionals ranging from sponsors and CROs, to investigative sites, technology solutions and niche providers.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 6/15/2016 via PR Newswire

The WIRB-Copernicus Group, will purchase Clinical Trial Applications from karmadata

synopsis: WIRB-Copernicus Group, one of the world's leading providers of solutions that measurably improve the quality of clinical research, will acquire from karmadata a suite of proprietary applications designed to facilitate the management of clinical trial data. karmadata is the market leader in clinical trial database and decision support applications.
buyer parent: Arsenal Capital Partners
buyer: The WIRB-Copernicus Group
WIRB-Copernicus Group (WCG) is one of the world's leading providers of solutions that measurably improve the quality and efficience of clinical research. WCG enables biopharmaceutical companies, Clinical Services Organizations and institutions to accelerate the delivery of new treatments. "
seller: karmadata
Karmadata is able to standardize and link the world's healthcare data ranging from leading open data sources to priva pharmacy and medical claims. Its propriety applications are designed to facilitate the management of clinical trial data.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 9/24/2014 via PR Newswire

The WIRB-Copernicus Group, acquired ePharmaSolutions, Inc.

synopsis: WIRB-Copernicus Group (WCG), the world's largest provider of regulatory and ethical review services for clinical research, announced that ePharmaSolutions (ePS) has joined its group of companies. ePharmaSolutions is a leading provider of eClinical solutions and technology-enabled services that improve the conduct of clinical trials.
buyer parent: Arsenal Capital Partners
buyer: The WIRB-Copernicus Group
WIRB-Copernicus Group (WCG) is the world's largest provider of regulatory and ethical solutions for clinical research, including Institutional Review Board (IRB) and Institutional Biosafety Committee (IBC) review. "
target: ePharmaSolutions, Inc.
ePharmaSolutions is a leading provider of eClinical solutions and specialty clinical services that help improve the way trial sites are selected, trained, activated and managed to exceed enrollment goals.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/8/2013 via PR Newswire

The WIRB-Copernicus Group, acquired IRBNet

synopsis: Arsenal Capital Partners, a private equity firm that invests in middle market healthcare and specialty industrial companies, announced the acquisition by its portfolio company, The WIRB-Copernicus Group, of Research Dataware, LLC, software developer and provider of IRBNet, the leading software application supporting institutional review boards.
buyer parent: Arsenal Capital Partners
buyer: The WIRB-Copernicus Group
With more than 60 years of combined experience reviewing research protocols and study-related information, it is the mission of The WIRB-Copernicus Group to meet the highest standards of ethics and science, and to ensure the safety and welfare of subjects worldwide. "
target: IRBNet
IRBNet offers the world's leading and most widely used electronic solution for managing research compliance for institutions of any size, with more than 1,600 large, medium and small research institutions, boards and research sites registered on the National Research Network®.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/16/2015 via PR Newswire

Schulman Associates Institutional Review Board, acquired Absolute Research

synopsis: Schulman Associates IRB, Inc., a customer service and technology company, has acquired Absolute Research. Absolute Research provides protection for human subjects involved in research while supporting a research enterprise. Absolute Research allows research administrators to navigate obstacles for biomedical and social-behavioral research.
buyer: Schulman Associates Institutional Review Board
Schulman Associates IRB is a leader in the protection of human research participants that offers IRB review services to clinical trial sponsors, CROs, and institutions. Schulman offers consulting services that improve clinical studies, data integrity and the protection of human subjects. "
target: Absolute Research
AbsoluteResearch accesses information to advise investigators on regulatory issues and make decisions for an IRB office. Their tools use experiences in IRB Management as well as Bioethics and with their Web-Based Solution they enable Research Institutes to analyze guidance from regulatory agencies.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/14/2017 via Company Press Release

Cressey & Co., Spectrum Equity, acquired Verisys Corporation

synopsis: Verisys Corporation, a leading provider of technology solutions and primary-source data on healthcare professionals and businesses, announced that Spectrum Equity, along with Cressey & Company and Verisys CEO John P. Benson, have made a significant growth equity investment in the Company.
buyer: Spectrum Equity
buyer: Cressey & Co.
Spectrum Equity is a leading growth equity firm providing capital and strategic support to innovative Internet, software and information services companies. Cressey & Company LP is a private investment firm focused exclusively on investing in and building leading healthcare businesses. "
target: Verisys Corporation
Verisys is the leading provider of health care credentialing services with the most current, accurate, and comprehensive data and technology tools. Since 1992, Verisys has been leading the health care industry by providing the highest quality data coupled with deep health care industry experience.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/5/2015 via BusinessWire

LexisNexis Risk Solutions, acquired Health Market Science, Inc.

synopsis: LexisNexis® Risk Solutions, a division of Reed Elsevier, announced it has acquired Health Market Science (HMS), a leading supplier of high-quality data on health care professionals and an administrator of one of the largest practitioner-level medical claims databases in the U.S.
buyer parent: Reed Elsevier
buyer: LexisNexis Risk Solutions
LexisNexis Risk Solutions is a leader in providing essential information that helps customers across industries and government predict, assess and manage risk. They are a leading supplier of data and data management solutions for the health care industry. "
target parent: Edison Partners
target: Health Market Science, Inc.
Health Market Science (HMS), helps businesses and government entities solve complex business challenges centered on healthcare provider information. HMS develops agile solutions so their clients can improve compliance, reduce operational costs and maximize market opportunities in real time.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 9/1/2010 via PR Newswire

Thomson Reuters, acquired Healthcare Data Management, Inc.

synopsis: Thomson Reuters, the world's leading source of intelligent information for businesses and professionals, announced that it has acquired Healthcare Data Management, Inc. Effective immediately, the company will become part of the Healthcare & Science business of Thomson Reuters.
buyer: Thomson Reuters (TRI:$5,921.00)
Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. Powered by the world's most trusted news organization, Thomson Reuters combine industry expertise with innovative technology to deliver critical information to leading decision makers. "
target: Healthcare Data Management, Inc.
Healthcare Data Management was a pioneer in the establishment of modeling employee health benefit plans and using data-driven metrics to monitor plan performance.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA

Like ePharmaSolutions, Inc.


read more

ePharmaSolutions, Inc.

MedSciNet

Greenphire, Inc

TrialTech Medical Inc.

Viedoc

Clinical Trial Connect, LLC

THREAD Research

OmniComm Systems, Inc.

Medidata

Custodix N.V.

GoBalto

Sylogent

Parallel 6

SecureConsent

Clinverse, Inc.

Medsight Solutions Inc.

ClinIntel Ltd.

Blueprint Clinical

DecisionView, Inc.

ClearTrial, LLC.

read more

ePharmaSolutions, Inc.

Polaris Biopharma Consulting

read more

Trifecta

Waife & Associates, Inc.

First Clinical Research LLC

KMR Group

Metrics Champion Consortium

ACI Clinical

Patient Genesis

MedAvante, Inc.

ProPhase, LLC

ThreeWire, Inc.

CenterWatch, Inc.

karmadata

ePharmaSolutions, Inc.

IRBNet

read more

Absolute Research

Verisys Corporation

Health Market Science, Inc.

Healthcare Data Management, Inc.

Geography
Matching Companies
Ticker: CHNG
 
 
 
 
 
 
 
 
Change Healthcare Corporation
Change Healthcare Corporation
Change Healthcare is a leading independent healthcare technology company that provides data and analytics-driven solutions to improve clinical, financial and patient engagement outcomes in the U.S. healthcare system.
year
2020
rev ($mm)
$1,646.91
EBITDA ($mm)
EBIT ($mm)
($155.95)
Net Income ($mm)
Employees
15000
  • drill down
  • watch
Ticker: TRHC
 
 
 
 
 
 
 
 
Tabula Rasa Healthcare
Tabula Rasa Healthcare
Tabula Rasa HealthCare (TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk.
year
2018
rev ($mm)
$204.27
EBITDA ($mm)
$16.27
EBIT ($mm)
$1.63
Net Income ($mm)
Employees
952
  • drill down
  • watch
Ticker: ZMD
 
 
 
 
 
 
 
 
ZoomMed Inc.
ZoomMed Inc.
Zoommed Inc. develops and markets various computer applications for healthcare professionals in Canada. The company builds and operates the ZoomMed Communication Network, a clinical interoperable information exchange network between physicians and various other stakeholders of the healthcare sector.
year
2014
rev ($mm)
$6.08
EBITDA ($mm)
$2.65
EBIT ($mm)
$2.78
Net Income ($mm)
Employees
40
  • drill down
  • watch
Ticker: ASX:MDR
 
 
 
 
 
 
 
 
MedAdvisor Limited
MedAdvisor Limited
MedAdvisor is a world class medication management platform focused on addressing the gap and burden of medication adherence. The highly automated Australian software system connects patients to their local pharmacy, providing them with real time access to their personal medication records.
year
2016
rev ($mm)
$1.05
EBITDA ($mm)
($2.13)
EBIT ($mm)
($2.15)
Net Income ($mm)
Employees
  • drill down
  • watch
Ticker: AIM:INS
 
 
 
 
 
 
 
 
Instem
Instem
Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide.
year
2020
rev ($mm)
$38.90
EBITDA ($mm)
$6.31
EBIT ($mm)
$5.20
Net Income ($mm)
$3.13
Employees
304
  • drill down
  • watch
Ticker: SYPT
 
 
 
 
 
 
 
 
Scrypt, Inc.
Scrypt, Inc.
Since 1998, Austin-based Scrypt, Inc. has been creating elegant document productivity tools for healthcare that eliminate manual processes and paper to save time and money. Scrypt has more than 30,000 customers across all 50 states.
year
2009
rev ($mm)
$0.27
EBITDA ($mm)
($0.85)
EBIT ($mm)
($0.91)
Net Income ($mm)
Employees
7
  • drill down
  • watch
Ticker: DATA
 
 
 
 
 
 
 
 
DATATRAK International, Inc.
DATATRAK International, Inc.
DATATRAK International, Inc. is a worldwide ASP for the EDC industry. The Company provides a suite of software products supporting the use of DATATRAK EDC(TM) and related services to the pharmaceutical, biotechnology, and medical device industries.
year
2012
rev ($mm)
$9.72
EBITDA ($mm)
($1.37)
EBIT ($mm)
($1.53)
Net Income ($mm)
Employees
  • drill down
  • watch